Skip to Main Content

Advertisement

Umbrella Alt Text
Cart
header search
Search
Skip Nav Destination

Issue Archive

Volume 130, Issue 10
September 7 2017
Issue Cover

Table of Contents

INSIDE BLOOD COMMENTARIES

INSIDE BLOOD COMMENTARY
Checking in: T cells against multiple myeloma
Clinical Trials & Observations
Shaji K. Kumar
View Articletitled, Checking in: T cells against multiple myeloma
INSIDE BLOOD COMMENTARY
Ticagrelor breaks up the tumor-platelet party
Annachiara Mitrugno,Owen J. T. McCarty
View Articletitled, Ticagrelor breaks up the tumor-platelet party
INSIDE BLOOD COMMENTARY
Anemia and bleeding in thrombocytopenic patients
Jeffrey L. Carson,Simon J. Stanworth
View Articletitled, Anemia and bleeding in thrombocytopenic patients
INSIDE BLOOD COMMENTARY
Haplo, we have a problem
Christopher S. Hourigan
View Articletitled, Haplo, we have a problem

REVIEW ARTICLE

Pathophysiology of thrombotic thrombocytopenic purpura
J. Evan Sadler
View Articletitled, Pathophysiology of thrombotic thrombocytopenic purpura

CLINICAL TRIALS AND OBSERVATIONS

Pembrolizumab, pomalidomide, and low-dose dexamethasone for relapsed/refractory multiple myeloma
Clinical Trials & Observations
Ashraf Badros,Elizabeth Hyjek,Ning Ma,Alexander Lesokhin,Ahmet Dogan,Aaron P. Rapoport,Mehmet Kocoglu,Emily Lederer,Sunita Philip,Todd Milliron,Cameron Dell,Olga Goloubeva,Zeba Singh
View Articletitled, Pembrolizumab, pomalidomide, and low-dose dexamethasone for relapsed/refractory multiple myeloma
Supplemental data
Pomalidomide, bortezomib, and dexamethasone for patients with relapsed lenalidomide-refractory multiple myeloma
Clinical Trials & Observations
Jonas Paludo,Joseph R. Mikhael,Betsy R. LaPlant,Alese E. Halvorson,Shaji Kumar,Morie A. Gertz,Suzanne R. Hayman,Francis K. Buadi,Angela Dispenzieri,John A. Lust,Prashant Kapoor,Nelson Leung,Stephen J. Russell,David Dingli,Ronald S. Go,Yi Lin,Wilson I. Gonsalves,Rafael Fonseca,P. Leif Bergsagel,Vivek Roy,Taimur Sher,Asher A. Chanan-Khan,Sikander Ailawadhi,A. Keith Stewart,Craig B. Reeder,Paul G. Richardson,S. Vincent Rajkumar,Martha Q. Lacy
View Articletitled, Pomalidomide, bortezomib, and dexamethasone for patients with relapsed lenalidomide-refractory multiple myeloma
Supplemental data

IMMUNOBIOLOGY AND IMMUNOTHERAPY

Analysis of the recovery of CD247 expression in a PID patient: insights into the spontaneous repair of defective genes
Brief Report
Alfonso Blázquez-Moreno,Adriana Pérez-Portilla,Miriam Agúndez-Llaca,Daniela Dukovska,Mar Valés-Gómez,Cigdem Aydogmus,Aydan Ikinciogullari,José R. Regueiro,Hugh T. Reyburn
View Articletitled, Analysis of the recovery of CD247 expression in a PID patient: insights into the spontaneous repair of defective genes
Supplemental data

LYMPHOID NEOPLASIA

Novel variants in NUDT15 and thiopurine intolerance in children with acute lymphoblastic leukemia from diverse ancestry
Clinical Trials & Observations Brief Report
Takaya Moriyama,Yung-Li Yang,Rina Nishii,Hany Ariffin,Chengcheng Liu,Ting-Nien Lin,Wenjian Yang,Dong-Tsamn Lin,Chih-Hsiang Yu,Shirley Kham,Ching-Hon Pui,William E. Evans,Sima Jeha,Mary V. Relling,Allen Eng-Juh Yeoh,Jun J. Yang
View Articletitled, Novel variants in <em>NUDT15</em> and thiopurine intolerance in children with acute lymphoblastic leukemia from diverse ancestry
Supplemental data

MYELOID NEOPLASIA

A FOXO1-induced oncogenic network defines the AML1-ETO preleukemic program
Shan Lin,Anetta Ptasinska,Xiaoting Chen,Mahesh Shrestha,Salam A. Assi,Paulynn S. Chin,Maria R. Imperato,B. J. Aronow,Jingsong Zhang,Matthew T. Weirauch,Constanze Bonifer,James C. Mulloy
View Articletitled, A FOXO1-induced oncogenic network defines the AML1-ETO preleukemic program
Supplemental data

PHAGOCYTES, GRANULOCYTES, AND MYELOPOIESIS

The atypical receptor CCRL2 is required for CXCR2-dependent neutrophil recruitment and tissue damage
Annalisa Del Prete,Laura Martínez-Muñoz,Cristina Mazzon,Lara Toffali,Francesca Sozio,Lorena Za,Daniela Bosisio,Luisa Gazzurelli,Valentina Salvi,Laura Tiberio,Chiara Liberati,Eugenio Scanziani,Annunciata Vecchi,Carlo Laudanna,Mario Mellado,Alberto Mantovani,Silvano Sozzani
View Articletitled, The atypical receptor CCRL2 is required for CXCR2-dependent neutrophil recruitment and tissue damage
Supplemental data

PLATELETS AND THROMBOPOIESIS

Role of ADP receptors on platelets in the growth of ovarian cancer
Min Soon Cho,Kyunghee Noh,Monika Haemmerle,Dan Li,Hyun Park,Qianghua Hu,Takeshi Hisamatsu,Takashi Mitamura,Sze Ling Celia Mak,Satya Kunapuli,Qing Ma,Anil K. Sood,Vahid Afshar-Kharghan
View Articletitled, Role of ADP receptors on platelets in the growth of ovarian cancer
Supplemental data

RED CELLS, IRON, AND ERYTHROPOIESIS

Immunoassay for human serum erythroferrone
Brief Report
Tomas Ganz,Grace Jung,Arash Naeim,Yelena Ginzburg,Zahra Pakbaz,Patrick B. Walter,Léon Kautz,Elizabeta Nemeth
View Articletitled, Immunoassay for human serum erythroferrone
Supplemental data

TRANSFUSION MEDICINE

Laboratory predictors of bleeding and the effect of platelet and RBC transfusions on bleeding outcomes in the PLADO trial
Lynne Uhl,Susan F. Assmann,Taye H. Hamza,Ryan W. Harrison,Terry Gernsheimer,Sherrill J. Slichter
View Articletitled, Laboratory predictors of bleeding and the effect of platelet and RBC transfusions on bleeding outcomes in the PLADO trial
Supplemental data

TRANSPLANTATION

Circulating dsDNA, endothelial injury, and complement activation in thrombotic microangiopathy and GVHD
Nicholas J. Gloude,Pooja Khandelwal,Nathan Luebbering,Dana T. Lounder,Sonata Jodele,Matthew N. Alder,Adam Lane,Alyss Wilkey,Kelly E. Lake,Bridget Litts,Stella M. Davies
View Articletitled, Circulating dsDNA, endothelial injury, and complement activation in thrombotic microangiopathy and GVHD

LETTERS TO BLOOD

Absence of driver mutations in persistent polyclonal B-cell lymphocytosis with binucleated lymphocytes
Bruno Tesson,Sarah Huet,Béatrice Grange,Laurent Jallades,Lucile Baseggio,Pascale Felman,Alexandra Traverse-Glehen,Jean-Pierre Magaud,Jean-Christophe Lega,Christine Bole-Feysot,Gilles Salles,Evelyne Callet-Bauchu,Pierre Sujobert
View Articletitled, Absence of driver mutations in persistent polyclonal B-cell lymphocytosis with binucleated lymphocytes
Supplemental data
A new tool for rapid and reliable diagnosis of HLA loss relapses after HSCT
Müberra Ahci,Cristina Toffalori,Evelien Bouwmans,Pietro Crivello,Chiara Brambati,Cinzia Pultrone,Karin Stempelmann,Douglas Bost,Benedetta Mazzi,Dietrich W. Beelen,Fabio Ciceri,Wietse Mulder,Katharina Fleischhauer,Luca Vago
View Articletitled, A new tool for rapid and reliable diagnosis of HLA loss relapses after HSCT
Supplemental data

BLOOD WORK

The beauty and the beast: lymphoma-like morphology of myeloid blast phase in CML
Anne Marie Asemissen,Judith Dierlamm
View Articletitled, The beauty and the beast: lymphoma-like morphology of myeloid blast phase in CML
Sickle cell trait with β-thalassemia, elliptocytosis, and thrombocytosis
Jamie L. Lombardo,David T. Lynch
View Articletitled, Sickle cell trait with β-thalassemia, elliptocytosis, and thrombocytosis
  • Cover Image

    Cover Image

    issue cover

    Three-dimensional structure of the human NUDT15 protein. Green and cyan indicate chain A and B in the NUDT15 homodimer. Red and blue colors highlight amino acid residues affected by genetic polymorphisms that are related to thiopurine drug toxicity in patients. The NUDT15 substrate thioguanine monophosphate is shown in a stick-ball representation. See the article by Moriyama et al on page 1209.

  • PDF Icon PDF LinkFront Matter
  • PDF Icon PDF LinkTable of Contents
  • PDF Icon PDF LinkBack Matter
  • PDF Icon PDF LinkEditorial Board
All Issues

Advertisement

Asciminib is a novel inhibitor of ABL1 and ABL2 gene fusions in ALL but requires the ABL SH3 domain for efficacy
NGS-based stratification refines the risk stratification in T-ALL and identifies a Very High-Risk subgroup of patients
Foxo1 is an iron-responsive transcriptional factor regulating systemic iron homeostasis
How I Treat Low-risk Polycythemia Vera Patients who Require Cytoreduction
How I manage major hemorrhage

Advertisement

Advertisement

  • American Society of Hematology
  • 2021 L Street NW, Suite 900
  • Washington, DC 20036
  • TEL +1 202-776-0544
  • FAX +1 202-776-0545

ASH Publications

American Society of Hematology

Copyright 2024 by American Society of Hematology
 
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal

Advertisement